A. Fasanmade

发表

Absence of Adverse Effects in Cynomolgus Macaques Treated with CNTO 95, a Fully Human Anti-αv Integrin Monoclonal Antibody, Despite Widespread Tissue Binding

B. Saville, H. Jang, Q. Jiao, 2005, Clinical Cancer Research.

Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment

O. O’Connor, A. Goy, R. Ramchandren, 2016, British journal of clinical pharmacology.

Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody–Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies

D. Ryan, W. Messersmith, T. Kalebic, 2016, Clinical Cancer Research.

Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris.

A. Gottlieb, C. Wagner, U. Chaudhari, 2003, Journal of the American Academy of Dermatology.

Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor- (cid:1) , in Patients With Moderate-to-Severe Heart Failure Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial Clinical Investigation and Rep

M. Packer, J. Willerson, K. Lo, 2003 .

Comparison of safety, efficacy and pharmacokinetics for 3 and 6 mg/kg infliximab plus methotrexate therapy in JRA patients

C. Wouters, R. Saurenmann, N. Wulffraat, 2005 .

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension

C. Wouters, P. Woo, E. Silverman, 2009, Annals of the rheumatic diseases.

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

W. Sandborn, W. Reinisch, B. Feagan, 2015, Alimentary pharmacology & therapeutics.

Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.

Honghui Zhou, H. Davis, A. Fasanmade, 2011, Clinical therapeutics.

O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings.

R. Schilsky, M. Dolan, M. Ratain, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.

M. Ratain, S. Lippman, R. Stupp, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study

Huyuan Yang, Y. Bang, Chia‐Chi Lin, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

PHARMACOKINETICS AND DISPOSITION Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

Honghui Zhou, H. Davis, J. Johanns, 2009 .

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.

A. Olson, H. Davis, R. Strauss, 2010, International journal of clinical pharmacology and therapeutics.

Kinetics of thermal decomposition of 4-carboxyl-2,6-dinitrobenzenediazonium ion (CDNBD).

A. Fasanmade, O. Idowu, A. Olaniyi, 2005, Journal of AOAC International.

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.

E. Keystone, A. Kavanaugh, E. S. St. Clair, 2002, Arthritis and rheumatism.

Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial

E. Chung, M. Packer, J. Willerson, 2003, Circulation.

Gelation kinetics of dilute hemoglobin from sickle cell anemia patients.

A. Fasanmade, 1996, Hemoglobin.

Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis

Honghui Zhou, Zhenhua Xu, H. Davis, 2008, Journal of clinical pharmacology.

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C

Huyuan Yang, P. Enzinger, J. Bendell, 2017, Investigational New Drugs.

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C

J. Bendell, M. Alsina, W. Messersmith, 2017, Investigational New Drugs.

Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer.

M. Ratain, E. Vokes, J. Kugler, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension

C. Wouters, P. Woo, Z. Balogh, 2008, Pediatric Rheumatology Online Journal.

Three-dimensional derivative spectrochimatograms in high-performance liquid chromatography and their implications for peak homogeneity validation

A. Fell, H. P. Scott, A. Fasanmade, 1986 .

Application of Computer-Aided Spectral Deconvolution Technique in Validation of High Performance Liquid Chromatographic Peaks

A. Fell, A. Fasanmade, 1992 .

Computer-aided time domain differentiation in high-performance liquid chromatography

A. Fell, A. Fasanmade, 1989 .

Determination of chlorpromazine and its sulphoxide in pharmaceutical dosage forms by third-order derivative ultraviolet spectroscopy.

A. Fell, A. Fasanmade, 1985, The Analyst.

Ultraviolet Spectral Features Affecting Computer-Aided Multiwavelength Quantitation of Multicomponent Mixtures Using Phenothiazines as Model

A. Fasanmade, 1994 .

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.

C. Wouters, R. Saurenmann, N. Wulffraat, 2007, Arthritis and rheumatism.

Quinacrine induces cytochrome c-dependent apoptotic signaling in human cervical carcinoma cells

A. Kong, D. Qato, A. Fasanmade, 2001, Archives of pharmacal research.

Immunodynamics of methylprednisolone induced T‐cell trafficking and deactivation using whole blood lymphocyte proliferation techniques in the rat

W. Jusko, A. Fasanmade, A. Fasanmade, 1999, Biopharmaceutics & drug disposition.

Evaluation of Dimethylformamide (DMF) as an Organic Modifier in Hydrophobicity Index (Rm) Determination.

A. Fasanmade, O. Idowu, A. Olaniyi, 2002 .

MLN0264, an investigational antiguanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) malignancies: Phase I study.

D. Ryan, W. Messersmith, T. Kalebic, 2014 .

Phase 1/2 Study of Brentuximab Vedotin in Pediatric Pts with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 HL Data

K. Neville, F. Locatelli, S. Daw, 2014 .

Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm

K. Neville, S. Daw, Angelo Rosolen, 2013 .

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension

S. Visvanathan, E. Giannini, D. Lovell, 2009, Annals of the rheumatic diseases.